Clinical trial • Not applicable • Endocrinology|Other
INDOCYANINE GREEN for Hypothyroidism|Hypoparathyroidism
Not applicable trial of INDOCYANINE GREEN for Hypothyroidism|Hypoparathyroidism.
Overview
- Trial Therapeutic Area
- Endocrinology|Other
- Trial Disease
- Hypothyroidism|Hypoparathyroidism
- Trial Stage
- Not applicable
- Drug Modality
- Diagnostic agent
Key dates
- Initial CTIS Submission Date
- 25-10-2023
- First CTIS Authorization Date
- 24-01-2024
Trial design
Randomised, two arms: arm with intraoperative indocyanine green (indocyanine green) arteriography (intravenous administration; product maximum total dose reported as 5 mg/kg) versus arm without icg (standard surgery without icg arteriography).-controlled Not applicable trial across 3 sites in Spain.
- Randomised
- Yes
- Comparator
- Two arms: Arm with intraoperative indocyanine green (INDOCYANINE GREEN) arteriography (intravenous administration; product maximum total dose reported as 5 mg/kg) versus arm without ICG (standard surgery without ICG arteriography).
- Target Sample Size
- 394
- Trial Duration For Participant
- 365
Eligibility
Recruits 394 The protocol states: "The patient or legal guardian can understand the study and agrees to participate by signing the written informed consent." Vulnerable population selection is marked as not selected (isVulnerablePopulationSelected=false). Consent is required from the patient or legal guardian as specified. No assent process or age‑specific consent documents or additional vulnerable-population procedures are described..
- Vulnerable Population
- The protocol states: "The patient or legal guardian can understand the study and agrees to participate by signing the written informed consent." Vulnerable population selection is marked as not selected (isVulnerablePopulationSelected=false). Consent is required from the patient or legal guardian as specified. No assent process or age‑specific consent documents or additional vulnerable-population procedures are described.
Inclusion criteria
- {"criterion_text":"- Patients ≥18 years of age with a surgical indication for total thyroidectomy with or without central cervical lymph node dissection due to thyroid disease."}
- {"criterion_text":"- The patient or legal guardian can understand the study and agrees to participate by signing the written informed consent."}
Exclusion criteria
- {"criterion_text":"- Previous surgical intervention on the thyroid or parathyroid gland."}
- {"criterion_text":"- Evidence of associated hyperparathyroidism requiring a parathyroidectomy in the same surgical procedure."}
- {"criterion_text":"- Patients with known contraindications to ICG."}
Endpoints
Primary endpoints
- {"endpoint_text":"- Number (percentage) of PG preserved with intraoperative ICG arteriography and the number (percentage) of preserved PG without it.","definition_or_measurement_approach":"Measured as the number and percentage of parathyroid glands (PG) preserved in each arm: with intraoperative ICG arteriography versus without ICG arteriography."}
Secondary endpoints
- {"endpoint_text":"- Preoperative calcium, total protein, vitamin D, and PTH serum levels","definition_or_measurement_approach":"Measured as laboratory serum values of total calcium, total protein, vitamin D and PTH prior to surgery."}
- {"endpoint_text":"- Number of well perfused GP in situ","definition_or_measurement_approach":"Count of parathyroid glands assessed intraoperatively as well perfused (in situ)."}
- {"endpoint_text":"- GP score according to the black and white system","definition_or_measurement_approach":"Scoring of parathyroid gland perfusion using the black and white system as defined in the protocol."}
- {"endpoint_text":"- Surgery duration","definition_or_measurement_approach":"Measured as operative time (duration of surgery)."}
- {"endpoint_text":"- Intraoperative PTH serum level","definition_or_measurement_approach":"Measurement of parathyroid hormone (PTH) levels during the operation."}
- {"endpoint_text":"- Serum PTH, calcium, and total protein levels at 24h after surgery","definition_or_measurement_approach":"Laboratory measurement of serum PTH, calcium and total protein at 24 hours post-operation."}
- {"endpoint_text":"- Serum PTH levels 1, 3, 6 and 12 months after surgery","definition_or_measurement_approach":"Laboratory measurement of serum PTH at 1, 3, 6 and 12 months post-operation."}
- {"endpoint_text":"- Presence or absence of hypoparathyroidism during the one-year follow-up. Hypoparathyroidism is defined as undetectable or inappropriately low serum PTH levels in the context of hypocalcemia.","definition_or_measurement_approach":"Determined during one-year follow-up by serum PTH and calcium: hypoparathyroidism defined as undetectable or inappropriately low PTH in the context of hypocalcemia."}
Recruitment
- Planned Sample Size
- 394
- Recruitment Window Months
- 36
- Consent Approach
- Written informed consent is required. The protocol states: "The patient or legal guardian can understand the study and agrees to participate by signing the written informed consent." No details on age‑specific documents, assent, or languages of consent forms are provided in the available record.
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 394
Spain
- Earliest CTIS Part Ii Submission Date
- 23-12-2023
- Latest Decision Or Authorization Date
- 24-01-2024
- Processing Time Days
- 32
- Number Of Sites
- 3
- Number Of Participants
- 394
Sites
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- General and Digestive Surgery
- Contact Person Name
- Oscar Vidal
- Contact Person Email
- ovidal@clinic.cat
- Site Name
- Hospital Universitario Basurto
- Department Name
- General and Digestive Surgery
- Contact Person Name
- Amaya Exposito
- Contact Person Email
- amaya.expositorodriguez@osakidetza.eus
- Site Name
- Bellvitge University Hospital
- Department Name
- General and Digestive Surgery
- Contact Person Name
- Pablo Moreno
- Contact Person Email
- 25108pml@gmail.com
Sponsor
Primary sponsor
- Full Name
- Bellvitge University Hospital
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Spain
Investigational products
- Investigational Product Name
- INDOCYANINE GREEN
- Active Substance
- INDOCYANINE GREEN
- Modality
- Diagnostic agent
- Routes Of Administration
- Intravenous administration
- Route
- Intravenous
- Authorisation Status
- Authorised for other indications (used in routine clinical practice for imaging)
- Maximum Dose
- 5 mg/kg
Related trials
Other published trials that may interest you.
- LETROZOLE for Polycystic ovary syndrome
- Estradiol for Diabetes mellitus | Perimenopause | Early postmenopause
- CHLORMADINONE ACETATE, ETHINYLESTRADIOL for Hormonal contraception
- MAGNESIUM L-ASPARTATE HYDROCHLORIDE TRIHYDRATE for Postoperative hypoparathyroidism
- TIRZEPATIDE for Overweight|Obesity|Polycystic ovary syndrome